Form 8-K Intellia Therapeutics, For: May 09
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Intellia Therapeutics (NTLA) PT Lowered to $29 at Citi
May 9, 2024 4:40 PM EDTCiti analyst David Lebowitz lowered the price target on Intellia Therapeutics (NASDAQ: NTLA) to $29.00 (from $31.00) while maintaining a Neutral rating.
The analyst comments "On the 1Q24 call, Intellia announced a new NTLA-2001 Ph3 trial in ATTR-PN (starting 2024). NTLA-2001s Ph3 MAGNITUDE... More
